BioCentury
ARTICLE | Clinical News

Infinity reports Phase I data for IPI-549 plus Opdivo in solid tumors

June 1, 2018 6:19 PM UTC

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) reported data from 30 evaluable patients with advanced solid tumors in the Phase I/Ib IPI-549-01 trial showing that IPI-549 plus PD-1 inhibitor Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) led to two partial responses in a patient each with adrenocortical carcinoma and microsatellite-stable gallbladder carcinoma. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The recommended Phase II dose is once-daily 40 mg oral IPI-549 plus Opdivo. The most common treatment-emergent adverse events were rash, pruritus, nausea, anemia, pyrexia and elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. The open-label, dose-escalation, U.S. trial is enrolling about 200 patients and is also evaluating IPI-549 as monotherapy...